A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ENDURE
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 19 Jun 2007 Status changed from planning to withdrawn prior to recruitment.
- 18 Nov 2006 New trial record.